Alnylam Pharmaceuticals Inc. (ALNY)

103.50
1.80 1.70
NASDAQ : Health Technology
Prev Close 105.26
Open 105.06
Day Low/High 103.10 / 106.08
52 Wk Low/High 70.76 / 153.99
Volume 137.94K
Avg Volume 997.60K
Exchange NASDAQ
Shares Outstanding 100.52M
Market Cap 10.52B
EPS -5.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Alnylam To Report New Clinical Results For Patisiran At The 4th Congress Of The European Academy Of Neurology

Alnylam To Report New Clinical Results For Patisiran At The 4th Congress Of The European Academy Of Neurology

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR)...

Over 700 Alnylam Employees Volunteer At The Company's 4th Annual "Helping Hands" Community Service Day

Over 700 Alnylam Employees Volunteer At The Company's 4th Annual "Helping Hands" Community Service Day

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today kicked off its fourth annual company-wide "Helping Hands" Community Service Day benefiting 23 organizations, including 16 organizations in the Greater Boston area...

Alnylam Reports Updated Positive Results From Phase 1/2 Study Of Lumasiran In Patients With Primary Hyperoxaluria Type 1 (PH1)

Alnylam Reports Updated Positive Results From Phase 1/2 Study Of Lumasiran In Patients With Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase (GO) for the treatment of...

Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For ALN-TTRsc02, A Subcutaneously Delivered Investigational RNAi Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis

Alnylam Receives Orphan Drug Designation From The United States Food & Drug Administration For ALN-TTRsc02, A Subcutaneously Delivered Investigational RNAi Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALN-TTRsc02, an investigational RNAi therapeutic for the...

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam To Webcast Presentations At Upcoming June Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Bernstein 34 th Annual Strategic Decisions Conference on Friday, June 1, 2018...

Alnylam Appoints Colleen Reitan To The Board Of Directors

Alnylam Appoints Colleen Reitan To The Board Of Directors

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylam's Board of Directors, effective June 1, 2018.

Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery Of RNAi Therapeutics

Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery Of RNAi Therapeutics

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has achieved delivery of novel small interfering RNA (siRNA) conjugates to the central nervous system (CNS) and is planning to advance a...

Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports First Quarter 2018 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter 2018 and highlighted recent progress in advancing its pipeline.

Alnylam Achieves Alignment With FDA On Accelerated Development Path For Lumasiran, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Achieves Alignment With FDA On Accelerated Development Path For Lumasiran, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company has reached alignment with the U.

Alnylam To Webcast Presentations At Upcoming May Investor Conferences

Alnylam To Webcast Presentations At Upcoming May Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Deutsche Bank 43 rd Annual Healthcare Conference on Tuesday, May 8, 2018...

Alnylam To Webcast Conference Call Discussing First Quarter 2018 Financial Results

Alnylam To Webcast Conference Call Discussing First Quarter 2018 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2018 on Thursday, May 3, 2018, after the U.

Alnylam Reports New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At The American Academy Of Neurology 2018 Annual Meeting

Alnylam Reports New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At The American Academy Of Neurology 2018 Annual Meeting

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis,...

Alnylam Receives Positive Opinion For Orphan Drug Designation In The European Union For ALN-TTRsc02, A Subcutaneously Delivered Investigational RNAi Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis

Alnylam Receives Positive Opinion For Orphan Drug Designation In The European Union For ALN-TTRsc02, A Subcutaneously Delivered Investigational RNAi Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending...

Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation And Other Pending Litigation

Alnylam Reaches Settlement Agreement With Dicerna Pharmaceuticals Resolving Trade Secret Misappropriation And Other Pending Litigation

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that it has entered into a settlement agreement with Dicerna Pharmaceuticals resolving trade secret misappropriation claims against Dicerna, and...

Alnylam And Collaborators To Present Clinical Study Results In Acute Hepatic Porphyrias (AHPs) At The 53rd International Liver Congress™ Of The European Association For The Study Of The Liver (EASL)

Alnylam And Collaborators To Present Clinical Study Results In Acute Hepatic Porphyrias (AHPs) At The 53rd International Liver Congress™ Of The European Association For The Study Of The Liver (EASL)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that Alnylam scientists and collaborators will present new results from the Phase 1 and Phase 1/2 open-label extension...

Alnylam Presents New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At The 16th International Symposium On Amyloidosis

Alnylam Presents New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At The 16th International Symposium On Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Company presented new results from the APOLLO Phase 3 study of patisiran, an investigational, RNAi...

Alnylam Receives European Medicines Agency PRIME Designation For Accelerated Assessment Of Lumasiran, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Receives European Medicines Agency PRIME Designation For Accelerated Assessment Of Lumasiran, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has granted access to its Priority Medicines (PRIME) scheme for lumasiran...

Regeneron And Alnylam Pharmaceuticals Announce Collaboration To Discover New Treatments For Nonalcoholic Steatohepatitis (NASH)

Regeneron And Alnylam Pharmaceuticals Announce Collaboration To Discover New Treatments For Nonalcoholic Steatohepatitis (NASH)

Collaboration based on new findings from the Regeneron Genetics Center® showing variant in HSD17B13 gene is associated with reduced risk of chronic liver diseases

Alnylam To Webcast Presentation At 17th Annual Needham Healthcare Conference

Alnylam To Webcast Presentation At 17th Annual Needham Healthcare Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 17 th Annual Needham Healthcare Conference on Wednesday,...

Alnylam To Report New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At The 16th International Symposium On Amyloidosis

Alnylam To Report New Clinical Results From The APOLLO Phase 3 Study Of Patisiran At The 16th International Symposium On Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational therapeutic for the treatment...

HATTR Amyloidosis Fact Sheet

HATTR Amyloidosis Fact Sheet

For many people living with a rare disease, such as hereditary ATTR (hATTR) amyloidosis, it can take years to be accurately diagnosed.

Alnylam Retains Global Rights To Lumasiran, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Retains Global Rights To Lumasiran, An Investigational RNAi Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 (PH1)

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that Sanofi Genzyme has declined its opt-in for the development and commercialization of lumasiran (ALN-GO1), an...

Alnylam To Webcast Presentations At Upcoming March Investor Conferences

Alnylam To Webcast Presentations At Upcoming March Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Cowen and Company...

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals Reports Fourth Quarter And Full Year 2017 Financial Results And Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year 2017 and highlighted recent progress in...

Alnylam To Webcast Presentations At Upcoming February Investor Conferences

Alnylam To Webcast Presentations At Upcoming February Investor Conferences

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 20 th Annual BIO CEO...

Alnylam Announces FDA Acceptance Of New Drug Application (NDA) And Priority Review Status For Patisiran, An Investigational RNAi Therapeutic For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Announces FDA Acceptance Of New Drug Application (NDA) And Priority Review Status For Patisiran, An Investigational RNAi Therapeutic For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2017 Financial Results

Alnylam To Webcast Conference Call Discussing Fourth Quarter And Full Year 2017 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2017 on Thursday, February...

Alnylam Announces EMA Acceptance Of Marketing Authorisation Application (MAA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Announces EMA Acceptance Of Marketing Authorisation Application (MAA) For Patisiran For The Treatment Of Hereditary ATTR (hATTR) Amyloidosis

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) and initiated its...

TheStreet Quant Rating: D (Sell)